Zydus Cadila files IND application for NME-ZYH2

Mumbai, Mar 27 (UNI) With continued success in its research programme, Zydus Cadila has filed another investigational new drug application for New Molecular Entity (NME)- ZYH2 with the Drug Controller General of India (DCGI).

A press release issued here today stated that this novel agent for treating diabetes has been designed and developed by Zydus Research Centre, the research wing of Zydus Cadila.

'ZYH2' has displayed a unique profile in pre-clinical studies, stated the release, adding that the NME has the potential to improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia.

It also works favourably to lower the elevated lipid levels.

In recent times, glitazones (rosiglitazone and pioglitazone) have been launched to treat increasing prevalence of insulin resistance in Type-II diabetes.

The pre-clinical studies on ZYH2 indicate that this NME may be more effective for diabetics by improving insulin resistance and lowering blood glucose levels without causing hypoglycemia and in also controlling the elevated tryglycerides level which is commonly found in such patients and may require specific intervention.

NME Research is one of the three focus areas of Zydus Research Programme. Under this, the focus has been on metabolic disorders, which includes dyslipidemia, diabetes and obesity and Inflammatory disorders.

UNI JJ KU SKB1536